Pharmacology of Catharanthus alkaloids;PHARMACOLOGIE DES CATHARANTHUS ALCALOIDES

Bulletin du Cancer

Volumn 83, Issue 3, 1996, Pages 176-186

  Leveque D ^a   Wihlm, J ^b   Jehl, F ^a  

^a Institut de Bacteriologie   (France)

^b CRLCC Paul Strauss   (France)

Author keywords

Catharanthus alkaloids; vinblastine; vincristine; vindesine; vinorelbine

Indexed keywords

NAVELBINE; VINBLASTINE; VINBLASTINE SULFATE; VINCRISTINE; VINCRISTINE SULFATE; VINDESINE; ANTINEOPLASTIC AGENT; CATHARANTHINE; DRUG DERIVATIVE; VINCA ALKALOID;

CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG METABOLISM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PHARMACODYNAMICS; PHARMACOLOGY; REVIEW; ANIMAL; CHEMISTRY; DRUG INTERACTION; DRUG TOLERANCE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG INTERACTIONS; DRUG TOLERANCE; HUMANS; VINBLASTINE; VINCA ALKALOIDS; VINCRISTINE; VINDESINE;

EID: 0030098960     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. 3H]-vincristine in man. Clin Pharmacol Ther 1977;22:430-8
2. Bender RA, Hamel E, Hande KR. Plant Alkaloids. In: Chabner BA, Collins JM, eds. Cancer chemotherapy: principles and practice. Philadelphie: Lippincott, 1990
3. Berlin J, King AC, Tutsch Findlay JW, Kohler P, Collier Clendeninn NJ, Wilding G. A Phase II study of vinblastine in combination with acrivastine in patients with advanced renal cell carcinoma. Invest New Drugs 1994;12:137-41
4. Boré P, Lena N, Imbert AM et al. Methotrexate-vindesine association in head and neck cancer: modification of methotrexate's hydroxylation in presence of vindesine. Cancer Chemother Pharmacol 1986;17:171-6
5. Boré P, Rahmani R, van Cantfort J, Focan C, Cano JP. Pharmacokinetics of a new anticancer drug, navelbine, in patients. Cancer Chemother Pharmacol 1989;23:247-51
6. Bradley G, Juranka PF, Ling V. Mechanism of multidrug resistance. Biochim Biophys Acta 1988;948:87-128
7. Brewer F, War JR. Verapamil reversal of vincristine resistance and cross-resistance patterns of vincristine-resistant chinese hamster ovary cells. Cancer Treat Rep 1987;71: 353-9
8. Cabral F, Barlow SB. Resistance to antimitotic agents as genetic probes of microtubule structure and function. Pharmacol Ther 1991;52:159-71
9. Chong CDK, Logothetis CJ, Savaraj N, Fritsche HA, Gietner AM, Samuels ML. The correlation of vinblastine pharmacokinetics to toxicity in testicular cancer patients. J Clin Pharmacol 1988;28:714-8
10. Cole SPC, Chanda ER, Dicke FP, Gerlach JH, Mirski SEL. Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II. Cancer Res 1991;51:3345-52
11. Cole SPC, Bhardwaj G, Gerlach JH et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258:1650-4
12. Cragg G, Suffness M. Metabolism of plant-derived anticancer agents. Pharmacol Ther 1988;37:425-61
13. Crom WR, de Graff SSN, Synold T et al. Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. J Pediatr 1994;125:642-9
14. Debal V, Allam N, Morjani H et al. Caractérisation du mécanisme de résistance croisée entre vincaalcaloïdes et taxoïdes dans la lignée de carcinome de vessie humain J82. Bull Cancer 1994;81:891-3
15. Deeley RG, Grant CE, Almquist EG et al. Multidrug resistance mediated by the 190 kDa MRP, a novel member of the ATP-binding cassette transporter superfamily. Proc Am Assoc Cancer Res 1994;35:698-9
16. Depierre A, Lebeau B, Chastang C et al and the French Cooperative Oncology Group. Result of a phase III randomized study of vinorelbine (V) versus vinorelbine-cisplatin (VP) in non small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1993;12:340
17. Desai ZR, Van den Berg HW, Bridges JM, Shanks RG. Can severe vincristine neurotoxicity be prevented? Cancer Chemother Pharmacol 1982;8:211-4
18. De Smet M, Van Belle SJP, Storme GA, Massart DL. High-performance liquid chromatographic determination of vinca alkaloids in plasma and urine. J Chromatrogr Biomed Appl 1985;345:309-21
19. Fedeli L, Colozza M, Boschetti E et al. Pharmacokinetics of vincristine in cancer patients treated with nifedipine. Cancer 1989;64:1805-11
20. Focan C, Mazy V, Zhou J, Rahmani R, Cano JP. Circadian variations of vindesine serum concentrations during continuous infusion. Annu Rev Chronopharmacol 1988;5:411-4
21. Fuks JZ, Egorin MJ, Aisner J et al. Therapeutic efficacy and pharmacokinetics of vindesine and vindesine-cisplatin in previously treated patients with non-small cell lung carcinoma. Cancer Chemother Pharmacol 1983;10:104-8
22. Ganapathi R, Hercbergs A, Grabowski D, Ford J. Selective enhancement of vincristine cytotoxicity in multidrug-resistant tumor cells by dilantin (phenytoin). Cancer Res 1993; 53:3262-5
23. Ganapathi R, Grabowski D, Weizer K, Ford J, Rice T, Bukowski R. Factors governing the selective enhancement of vinca-alkaloid cytotoxicity by phenytoin. Proc Am Assoc Cancer Res 1994;35:341
24. Goa KL, Faulds D. Vinorelbine. A review of its pharmacological properties and clinical use in cancer chemotherapy. Drugs & Aging 1994;5:200-34
25. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993;62:385-427
26. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SPC, Deemey RG. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 1994;54:357-61
27. Hacker MP. Toxicity of vinca alkaloids. In: Powis G, Hacker MP, eds. The toxicity of anticancer drugs. New York: Pergamon Press, 1991
28. Hillcoat BL. Priorities in experimental therapeutics - A surfeit of riches. Eur J Cancer Clin Oncol 1989;25:1263-9
29. Himes RH. Interactions of the catharanthus (vinca) alkaloids with tubulin and microtubules. Pharmacol Ther 1991; 51:257-67
30. Houghton JA, Houghton PJ, Hazelton BJ, Douglass EC. In situ selection of a human rhabdomyosarcoma resistant to vincristine with altered β-tubulins. Cancer Res 1985;45: 2706-12
31. Hunter J, Jepson MA, Tsuruo T, Simmons NL, Hirst BH. Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. J Biol Chem 1993; 268:14991-7
32. Hunter J, Hirst BH, Simmons NL. Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers. Pharm Res 1993;10:743-9
33. Jackson Jr DV, Castle MC, Bender RA. Biliary excretion of vincristine. Clin Pharmacol Ther 1978;24:101-7
34. Jackson Jr DV, Sethi VS, Spurr CL, McWhorter JM. Pharmacokinetics of vincristine in the cerebrospinal fluid of humans. Cancer Res 1981;41:1466-8
35. Jackson Jr DV, Sethi VS, Spurr CL et al. Pharmacokinetics of vincristine infusion. Cancer Treat Rep 1981;65:1043-8
36. Jackson Jr DV, Sethi VS, Long TR et al. Pharmacokinetics of vindesine bolus and infusion. Cancer Chemother Pharmacol 1984;13:114-9
37. Jehl F, Quoix E, Levêque D et al. Pharmacokinetic and preliminary metabolic fate of navelbine in humans as determined by high performance liquid chromatography. Cancer Res 1991;51:2073-6
38. Johnson IS, Armstrong JG, Gorman M, Burnett Jr JP. The vinca alkaloids: a new class of oncolytic agents. Cancer Res 1963;23:1390-1427
39. Jordan MA, Thrower D, Wilson L. Mechanism of inhibition of cell proliferation by vinca alkaloids. Cancer Res 1991; 51:2212-22
40. Jordan MA, Toso RJ, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 1993;90: 9552-6
41. Knick VC, Miller CG. In vivo derivation of a murine P388 leukemia subline resistant to 5′-nor-anhydrovinblastine (navelbine) and its cross-resistance profile. Proc Am Assoc Cancer Res 1992;33:462
42. Lechevalier T, Brisgand D, Douillard JY et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a european multicenter trial including 612 patients. J Clin Oncol 1994;12:360-7
43. Lena N, Imbert AM, Pignon T et al. Methotrexate-vindesine association in the treatment of head and neck cancer influence of vindesine on methotrexate's pharmacokinetic behavior. Cancer Chemother Pharmacol 1984;12:120-4
44. Levêque D, Jehl F, Quoix E, Breillout F. Clinical pharmacokinetics of vinorelbine alone and combined with cisplatin. J Clin Pharmacol 1992;32:1096-8
45. Levêque D, Merle-Melet M, Bresler L et al. Biliary elimination and pharmacokinetics of vinorelbine in micropigs. Cancer Chemother Pharmacol 1993;32:487-90
46. Levêque D, Quoix E, Dumont P et al. Pulmonary distribution of vinorelbine in patients with non-small-cell lung cancer. Cancer Chemother Pharmacol 1993;33:176-8
47. Lu K, Yap HY, Loo TL. Clinical pharmacokinetics of vinblastine by continuous intravenous infusion. Cancer Res 1983;43:1405-8
48. Mangeney P, Andriamialisoa Z, Lallemand JY, Langlois N, Langlois Y, Potier P. 5'nor-anhydrovinblastine. Prototype of a new class of vinblastine derivatives. Tetrahedron 1979;35:2175-9
49. Marquet P, Lachatre G, Debord J, Eichler B, Bonnaud F, Nicot G. Pharmacokinetics of vinorelbine in man. Eur J Clin Pharmacol 1992;42:545-7
50. Mirski SEL, Gerlach JH, Cole SPC. Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin. Cancer Res 1987;47:2594-8
51. Mitchinson T, Kirschner M. Dynamic instability of microtubule growth. Nature 1984;312:237-42
52. Nelson RL, Dyke RW, Root MA. Clinical pharmacokinetics of vindesine. Cancer Chemother Pharmacol 1979;2: 243-6
53. Nelson RL, Dyke RW, Root MA. Comparative pharmacokinetics of vindesine, vincristine and vinblastine in patients with cancer. Cancer Treatment Rev 1980;7 (Suppl):17-24
54. Noble RL. The discovery of the vinca alkaloids chemotherapeutic agents against cancer. Biochem Cell Biol 1990;68: 1344-51
55. Ohnuma T, Norton L, Andrejczuk A, Holland JF. Pharmacokinetics of vindesine given as an intravenous bolus and 24-H infusion in humans. Cancer Res 1985;45:464-9
56. Owellen RJ, Hartke CA. The Pharmacokinetics of 4-Acetyl tritium vinblastine in two patients. Cancer Res 1975;35: 975-80
57. Owellen RJ, Root MA, Hains FO. Pharmacokinetics of vindesine and vincristine in humans. Cancer Res 1977;37: 2603-7
58. Owellen RJ, Hartke CA, Hains FO. Pharmacokinetics and metabolism of vinblastine in humans. Cancer Res 1977;37: 2597-2602
59. Pinkerton CR, McDermott B, Philip T et al. Continuous vincristine infusion as part of a high dose chemoradiotherapy regimen: drug kinetics and toxicity. Cancer Chemother Pharmacol 1988;22:271-4
60. Pakrash V, Timasheff SN. Mechanism of interaction of vinca alkaloids with tubulin: catharanthine and vindoline. Biochemistry 1991;30:873-80
61. Rahmani R, Martin M, Favre R, Cano JP, Barbet J. Clinical pharmacokinetics of vindesine: repeated treatments by intravenous bolus injections. Eur J Cancer Clin Oncol 1984;20:1409-17
62. Rahmani R, Kleisbauer JP, Cano JP, Martin M, Barbet J. Clinical pharmacokinetics of vindesine infusion. Cancer Treat Rep 1985;69:839-44
63. Rahmani R, Guéritte F, Martin M, Just S, Cano JP, Barbet J. Comparative pharmacokinetics of antitumor vinca alkaloids: intravenous bolus injections of navelbine and related alkaloids to cancer patients and rats. Cancer Chemother Pharmacol 1986;16:223-8
64. Rahmani R, Bruno R, Iliadis A et al. Clinical pharmacokinetics of the antitumor drug navelbine (5′-noranhydrovinblastine). Cancer Res 1987;47:5796-9
65. 3H]navelbine in patients: comparative pharmacokinetics using radioactive and radioimmunologic determination methods. Anti Cancer Drugs 1991;2:405-10
66. Ratain MJ, Vogelzang NJ. Phase I and pharmacological study of vinblastine by prolonged continuous infusion. Cancer Res 1986;46:4827-30
67. Ratain MJ, Vogelzang NJ, Sinkule JA. Interpatient and intrapatient variability in vinblastine pharmacokinetics. Clin Pharmacol Ther 1987;41:61-7
68. Robinson HM. Vinca revisited - another happenstance in the discovery of vinblastine. Biochem Cell Biol 1991;69:581-2
69. Rowinski E, Donehower RC. The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmacol Ther 1991;52:35-84
70. Rowinsky E, Noe DA, Trump DL et al. Pharmacokinetic, bioavailability and feasibility study of oral vinorelbine in patients with solid tumors. J Clin Oncol 1994;12:1754-63
71. Schibler MJ, Barlow SB, Cabrai F. Elimination of permeability mutants from selections for drug resistance in mammalian cells. FASEB J 1989;3:163-8
72. Schlaifer D, Cooper MR, Attal M, Sartor AO, Trepel JB, Laurent G, Myers CE. Myeloperoxidase: an enzyme involved in intrinsic vincristine resistance in human myeloblastic leukemia. Blood 1993;81:482-9
73. Sethi VS, Jackson Jr DV, White DR et al. Pharmacokinetics of vincristine sulfate in adult cancer patients. Cancer Res 1981;41:3551-5
74. Sethi VS, Kimbal JC. Pharmacokinetics of vincristine sulfate in children. Cancer Chemother Pharmacol 1981;6: 111-5
75. Singer WD, Himes RH. Cellular uptake and tubulin binding properties of four vinca alkaloids. Biochem Pharmacol 1992;43:545-51
76. Solere P, Lucas C. Limites analytiques en pharmacocinétique clinique: l'exemple des vinca alcaloïdes. Bull Cancer 1991;78:775-87
77. 1-acid glycoprotein. Cancer Chemother Pharmacol 1982;10:40-2
78. Steele WH, King DJ, Barber HE, Hawksworth GM, Dawson AA, Petrie JC. The protein binding of vinblastine in the serum of normal subjects and patients with Hodgkin's disease. Eur J Clin Pharmacol 1983;24:683-7
79. Stewart DJ, Lu K, Benjamin RS et al. Concentrations of vinblastine in human intracerebral tumor and other tissues. J Neuro-Oncol 1983;1:139-44
80. Tobe SW, Siu LL, Jamal SA, Skorecki KL, Murphy GF, Warner E. Vinblastine and erythromycin: an unrecognized serious drug interaction. Cancer Chemother Pharmacol 1995;35:188-90
81. Toussaint C, Izzo J, Spielmann M et al. Phase I/II trial of continuous infusion vinorelbine for advanced breast cancer. J Clin Oncol 1994;12:2102-12
82. Urien S, Brée F, Breillout F, Bastian G, Krikorian A, Tillement JP. Vinorelbine high-affinity binding to human platelets and lymphocytes: distribution in human blood. Cancer Chemother Pharmacol 1993;32:231-4
83. Van den Berg HW, Desai ZR, Wilson R, Kennedy G, Bridges JM, Shanks RG. The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination. Cancer Chemother Pharmacol 1982;8:215-9
84. Van Tellingen O, Beijnen JH, Nooyen WJ. Analytical methods for the determination of vinca alkaloids in biological specimens: a survey of the literature. J Pharm Biomed Anal 1991;9:1077-82
85. Van Tellingen O, Sips JHM, Beijnen JH, Bult A, Nooijen WJ. Pharmacology, Bio-analysis and Pharmacokinetics of the vinca alkaloids and semi-synthetic derivatives [Review]. Anticancer Res 1992;12:1699-1716
86. Van Tellingen O, Beijnen JH, Nooijen WJ, Bull A. Tissue disposition, excretion and metabolism of vinblastine in mice as determined by high-performance liquid chromatography. Cancer Chemother Pharmacol 1993;32:286-92
87. Wendell KL, Wilson L, Jordan MA. Mitotic block in HeLa cells by vinblastine: ultrastructural changes in kinetochoremicrotubule attachment and in centrosomes. J Cell Sci 1993;104:261-74
88. Young JA, Howell SB, Green MR. Pharmacokinetics and toxicity of 5-day continuous infusion of vinblastine. Cancer Chemother Pharmacol 1984;12:43-5
89. Zhou-Pan XR, Sérée E, Zhou XJ et al. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. Cancer Res 1993;53:5121-6
90. Zhou XJ, Zhou-Pan R, Favre R, Rahmani R. Relative bioavailability of two oral formulations of navelbine in cancer patients. Biopharm Drug Dispos 1994;15:577-86